Oocyte maturity and preimplantation development in relation to follicle diameter in gonadotropin-releasing hormone agonist or antagonist treatments
|
|
- Shanon Stephens
- 5 years ago
- Views:
Transcription
1 IN VITRO FERTILIZATION Oocyte maturity and preimplantation development in relation to follicle diameter in gonadotropin-releasing hormone agonist or antagonist treatments Daniela Nogueira, Ph.D., a Shevach Friedler, M.D., b Morey Schachter, M.D., b Arieh Raziel, M.D., b Raphael Ron-El, M.D., b and Johan Smitz, Ph.D. a a Follicle Biology Laboratory, Free University of Brussels (Vrije Universiteit Brussel), Brussels, Belgium; and b IVF and Fertility Unit, Assaf Harofeh Medical Center, Tel Aviv University, Tel Aviv, Israel Objective: To analyze the distribution of oocytes nuclear maturational stages and intracytoplasmic sperm injection (ICSI) outcome in relation to follicular size, after controlled ovarian hyperstimulation (COH), using gonadotropinreleasing hormone (GnRH) antagonist or agonist protocols. Design: Prospective comparative study. Setting: Fertility unit in an academic hospital. Patient(s): Normo-ovulatory patients with unexplained, male and/or tubal factor infertility undergoing ICSI treatment. Intervention(s): Oocytes were retrieved from small (7 12 mm) and large follicles ( 12 mm). Main Outcome Measure(s): Oocyte nuclear maturation stage, fertilization and pre-implantation embryonic development of the mature ova evaluated. Result(s): Distribution of oocyte maturation stages from small follicles did not differ between the two COH protocols. From large follicles, a statistically significantly higher percentage of immature oocytes was retrieved after antagonist compared with agonist treatment (16 vs 11%, respectively). No statistically significant differences existed regarding ICSI outcome of mature ova within the same follicle diameter range between COH protocols. Inseminated ova from small follicles presented a significantly higher number of embryos with delayed development on day 3 after ICSI. Conclusion(s): A greater heterogeneity of maturity was found in the population of oocyte stages that were present after the antagonist protocol. Matured oocytes retrieved from small follicles generated embryos of lower developmental potential than oocytes derived from larger follicles. (Fertil Steril 2006;85: by American Society for Reproductive Medicine.) Key Words: Follicles, oocyte maturation, oocyte development, GnRH analogues Received December 27, 2004; revised and accepted August 11, Presented at the European Society of Human Reproduction (ESHRE) th Annual Meeting; Berlin, Germany; June 27 to 30, Reprint requests: Daniela Nogueira, Ph.D., Women and Infants Hospital, New England Medical Center, Tufts, 750 Washington Street, Box 036, Boston, Massachusetts (FAX: ; daniela_nogueira@yahoo.com). Gonadotropin-releasing hormone (GnRH) antagonists recently joined the armamentarium of clinically available GnRH analogues to prevent premature luteinizing hormone (LH) surges during controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF) (1 3). Although protocols using antagonists are of shorter duration compared with protocols using GnRH agonists, the preliminary reports of inferior rates of implantation and clinical pregnancies raised concerns (1 4). The potentially different effects of GnRH antagonists and agonists on ovarian folliculogenesis may lead to different responses and endocrine environments for maturing oocytes. Information about oocyte maturational stage in relation to follicular size after different superovulation protocols has been scanty. Early studies performed on IVF cycles using cumulus-enclosed oocytes indicated that oocytes retrieved from larger follicles, defined as 12 mm (5) or 16 mm (6 9), tended to achieve higher fertilization and cleavage rates. However, no difference in embryo quality was observed (5). Because oocyte denudation enables direct observation of developmental status, ICSI cycles facilitate precise assessment of oocyte nuclear maturation. Oocyte nuclear stage correlates with follicular diameter in some studies, but no studies have compared different COH protocols. In patients treated by short or long agonists COH protocols, a progressive and significant increase in the rates of polar body extruded oocytes was observed from small follicles, defined 578 Fertility and Sterility Vol. 85, No. 3, March /06/$32.00 Copyright 2006 American Society for Reproductive Medicine, Published by Elsevier Inc. doi: /j.fertnstert
2 as 12 mm (10, 11) or 16 mm (8, 9), to larger diameter follicles. Variable outcomes were reported following ICSI, including a significant reduction in fertilization rates of oocytes from small follicles (8) and a trend toward lower fertilization rate compared with oocytes from larger follicles (11). Other studies showed similar fertilization rates (9, 10). Our study aimed to determine the distribution of oocyte maturation stages and outcome of ICSI in relation to follicular diameter after using antagonist or agonist protocols for COH. MATERIALS AND METHODS Study Population Our prospective study enrolled all women consecutively treated with ICSI in the IVF unit at Assaf Harofeh Medical Center from December 2003 to March 2004 who agreed to participate. Informed consent was obtained from all participants, and the investigation received the approval of the institutional review board of the Assaf Harofeh Medical Center. To minimize confounding factors, patients diagnosed with polycystic ovaries or with poor response (fewer than four mature follicles on ultrasound before oocyte retrieval) were excluded from the study. Only one treatment cycle per patient was analyzed. Because the proportion of agonist and antagonist cycles in our center is 3 to 1, an antagonist cycle was recruited for the study after three recruited agonist cycles. A total of 97 patients was included, 71 treated by agonists and 26 by antagonists. Mean ages ( standard deviation) were years (range: 28 to 41 years) and years (range: 22 to 31 years) for the agonist and antagonist groups, respectively. Major indications for IVF/embryo transfer (ET) included male factor infertility (76%), male and tubal factor infertility (15%), and unexplained infertility (9%). COH, Oocyte Retrieval, and ICSI Patients included in the study were treated by routine COH protocols for IVF using either agonists or antagonists. In the agonist group, COH consisted of midluteal pituitary downregulation, using a daily dose of GnRH-a (nafarelin acetate, 200 mg three times a day, via intranasal spray; or triptorelin, 0.1 mg/day, via subcutaneous injection), followed by an individually adjusted daily dose of urinary or recombinant gonadotrophin injections. In the antagonist group, COH using daily injections of gonadotrophins was administered, followed by a daily dose of GnRH antagonist (0.25 mg of Cetrotide, Serono Laboratories, Geneva, Switzerland; or Orgalutran, Organon, Oss, the Netherlands) once a lead follicle of 12 mm was observed or serum estradiol levels had reached 400 pg/ml. Oocytes were retrieved 35 to 38 hours after administration of 5000 IU hcg, which was given according to similar criteria in both groups (i.e., presence of at least two leading follicles of 18 mm). Routine oocyte pick-up was performed using a 17G oocyte aspiration needle. Once follicles larger than 12 mm had been aspirated ( large ), the needle attached to the test tube was washed with HEPES-containing media, and a new tube was attached to the needle for aspiration of smaller follicles ( small ) measuring 7 to 12 mm. Follicles were aspirated using 80 mm Hg pressure. Follicular aspirates from large and small follicles were collected in separate plastic Falcon tubes. Oocyte denudation was performed 2 to 5 hours after the oocyte retrieval procedure (40 hours after hcg administration). Following oocyte denudation, oocytes of each COH protocol were classified according to intactness (degenerated or not) and nuclear maturational stages (germinal vesicle [GV], germinal-vesicle breakdown [GVBD], or polar body extruded [PB]) under an inverted microscope (magnification 200; 400). For PBextruded oocytes, ICSI was performed. Oocytes were cultured singly in droplets of G1 media (Vitrolife, Kungsbacka, Sweden). Fertilization was assessed 16 to 18 hours after injection, and normal fertilizations (presence of two pronuclei) was recorded. Embryonic cleavage and morphologic appearance were assessed 40 to 44 hours and 64 to 68 hours after ICSI. A morphologic score was given for each embryo according to the degree of fragmentation: 1, no fragmentation; 2, 20% fragmentation; 3, 20% to 50% fragmentation; 4, 50% fragmentation. The outcome of ICSI was compared in PB oocytes retrieved from small and large follicles. For later identification and data analysis, the clinical and laboratory files of each patient were assigned a common number that was different from the patient s medical record number. This ensured that the biologists who handled the oocytes and recorded the outcomes would be blinded to the COH protocols. Statistical Analysis Differences in oocyte maturational stages, as well as fertilization and cleavage rates, were calculated by chi-square test and Fischer s exact test, as appropriate. Differences in means between two variables were calculated using Student s t-test or the Mann-Whitney U-test, as appropriate. P.05 was considered statistically significant. Comparative statistics were performed to include all ICSI cycles. RESULTS Clinical IVF outcomes are described in Table 1. The recovery rate of oocytes was recorded only for the small follicles, and it was comparable after both COH protocols (56% and 52% in antagonist and agonist groups, respectively; P.05) (Table 2). Among oocytes from small follicles, a larger proportion was degenerated at retrieval after the antagonist protocol compared with the agonist (P.05). The distribution of oocyte maturation stages of oocytes from small follicles did not differ after COH protocols using antagonist or agonist. In both treatment groups, about Fertility and Sterility 579
3 TABLE 1 Clinical outcome of patients treated with gonadotropin-releasing hormone antagonist or agonist protocols. Antagonist (n 26) Agonist (n 71) P value a Day of hcg administration (mean SD) Mean dose of FSH/patient (IU per stimulation cycle) 2, , , ,092.4 NS E 2 at day of hcg (pg/ml) 2, , , , Mean no. of embryos transferred SD NS No. (%) of patients with cryopreservation 9 (34.6) 29 (40.8) NS No. (%) of cryopreserved embryos/cleaved embryos 29 (28.1) 157 (32.7) NS No. (%) of implanted embryos 10 (14.5) 38 (22.4) NS No. (%) of pregnancies 7 (26.9) 29 (40.1) NS Note: hcg human chorionic gonadotropin; FSH follicle-stimulating hormone; NS not statistically significant; SD standard deviation. a Mann-Whitney test, chi-square, or Fisher s exact test. 40% of oocytes retrieved from small follicles were at the PB stage (see Table 2). Among oocytes from large follicles, a higher proportion was at the GV stage (P.0001) and significantly fewer oocytes were at GVBD stage after the antagonist protocol. The proportion of PB oocytes was lower after the antagonist treatment, but this difference did not reach statistical significance (P.07). Comparing ICSI outcome between the antagonist and agonist treatments of PB oocytes retrieved from small or large follicles (Table 3), no statistically significant difference was observed regarding 2-PN fertilization rates or embryo developmental quality on day 2. Cleavage rates were comparable between the antagonist and agonist groups, with similar proportions of four-cell stage embryos on day 2 (approximately 60% from large follicle groups and approx- TABLE 2 Comparison of the distribution of oocyte nuclear maturation stages, between small and large follicles in patients treated by gonadotropin-releasing hormone antagonist or agonist controlled ovarian hyperstimulation protocols for intracytoplasmic sperm injection cycles. Follicular size Antagonist (n 26) Agonist (n 71) P value Small No. of oocytes Maturation stages GV (%) 34 (47) 124 (51) NS GVBD (%) 2 (3) 21 (9) NS PB (%) 31 (43) 93 (38) NS Degenerated (%) 5 (7) 5 (2).05 Large No. of oocytes Maturation stages GV (%) 25 (14) 37 (5).0001 GVBD (%) 3 (2) 47 (6).05 PB (%) 149 (83) 726 (88) NS Degenerated (%) 2 (1) 11 (1) NS Note: GV germinal vesicle; GVBD germinal-vesicle breakdown; NS not statistically significant; PB polar body extruded. 580 Nogueira et al. Oocyte development and follicle size Vol. 85, No. 3, March 2006
4 TABLE 3 Comparison of ICSI outcomes of oocytes with polar body extruded from small and large follicles, according to gonadotropin-releasing hormone antagonist or agonist protocols. Small follicles Large follicles Antagonist Agonist P value a Antagonist Agonist P value a No. of PB oocytes injected % 2-PN NS NS % Cleaved/2-PN NS NS Day 2 embryo developmental quality Mean no. of blastomeres SD NS NS Mean fragmentation score SD NS NS Day 3 embryo developmental quality Mean no. of blastomeres SD NS NS Mean fragmentation score SD NS NS Note: NS not statistically significant; PB polar body extruded; PN pronuclear. a Chi-square test or Student s t-test. imately 55% from small groups) and eight-cell stage on day 3 (approximately 35% from large and approximately 20% from small follicle groups). The outcome of ICSI on oocytes from small or large sibling follicles derived from the same patient did not show statistically significant differences regarding 2-PN fertilization rates, mean blastomere number, or embryo quality on days2or3(table 4). No differences were found regarding the percentage of day-2 embryos with 4 cells (72% from small vs. 74% from large follicles; not statistically significant). However, by day 3 after ICSI, the oocytes from small follicles generated more embryos presenting only four cells (P.05). Although more embryos from large follicles were at the eight-cell stage on day 3 compared with the small follicles (P.05), the proportion of embryos attaining at least eight cells ( 8 cells) did not reveal a statistically significant difference between the embryos from large (42%) and small (29%) follicles (P.08). Embryos generated from TABLE 4 Outcome of intracytoplasmic sperm injection in oocytes with polar body extruded according to follicular size of sibling follicles derived from the same patient. Small follicles Large follicles P value a No. of PB oocytes injected % 2-PN NS % Cleaved/2-PN NS Day 2 embryo developmental quality Mean no. of blastomeres SD NS Mean fragmentation score SD NS % 4-cell/total cleaved NS % 4-cell/total cleaved NS Day 3 embryo developmental quality Mean no. of blastomeres SD NS Mean fragmentation score SD NS % 4-cell/total cleaved % 8-cell/total cleaved Note: NS not statistically significant; PB polar body extruded; PN pronuclear. a Mann-Whitney test, chi-square, or Fisher s exact test. Fertility and Sterility 581
5 oocytes of small follicles had a lower capability for optimal rate of cleavage, with only 15% of embryos per total cleaved presenting four-cell stage on day 2 and subsequently presenting eight-cell stage on day 3. For large follicles, 31% of embryos per total cleaved had an optimal rate of cleavage from days 2 to 3 of culture. DISCUSSION Early studies performed after IVF (which does not require denudation of oocyte before insemination) indicated that oocytes retrieved from larger follicles tended to achieve higher fertilization and cleavage rates than the oocytes from follicles 12 mm (5) or 16 mm (6 9). However, no difference in embryo quality was observed (5). Scott et al. (12) suggested that, due to the lower recovery rates of mature oocytes from follicles 11 mm, the operating surgeon may choose not to aspirate these follicles. Follicles 15 mm provide the highest probability of retrieving mature oocytes (13). Exact assessment of oocytes maturational stage has been reported in a few studies that involved ICSI, where oocyte denudation is needed. In these studies, COH included agonists protocols only. The definition of small follicles varied from 16 mm to 10 mm in the studies located by our literature search. A progressive and significant increase in the rates of PB oocytes has been observed from small follicle groups of diameter 16 mm (8, 9) or 10 mm (10, 11) to the larger follicle groups. Moreover, a positive correlation has been observed between follicular diameter and fertilization rates and rates of embryos scored as good when oocytes were fertilized by ICSI (8, 10, 11). Similar rates of fertilization, cleavage, and implantation rates have been found by others, regardless of the size of the follicles from which oocytes were aspirated (small at 16 mm, or large at 16 mm) (9). Our review of the literature located no studies correlating oocyte maturational stage and follicular size according to COH protocol. Thus, our study was the first comparison of oocyte maturational rates after agonist or antagonist treatments. An important finding in our study was that a high percentage of PB extruded oocytes ( 40%) were retrievable from small follicles. This may be useful clinically; currently many IVF programs may routinely aspirate small follicles, regardless of the stimulation protocols applied. The reason for the high recovery of PB extruded oocytes from small follicles in our study is not clear. Although follicles are FSH-dependent when in antral stage, they can respond to FSH from the preantral stage onward. Recombinant FSH mrna is detected in follicles presenting only two or more layers of granulosa cells (14). Moreover, FSH upregulates expression of its own receptor and induces expression of LH receptor in granulosa cells. The prolonged exogenous FSH administration (up to when leading follicles are 18 mm) could have induced an increase in gene expression for LH receptors in granulosa cells even in the smaller follicles. Therefore, at the time of LH administration, the smaller follicles already would have achieved the ability to undergo meiotic maturation. The effects of GnRH-analogues on the ovary, the oocyte, follicle, embryo and endometrium are a matter of debate (15). At time of retrieval, about half the population of oocytes from small follicles were found to be at GV-stage, independent of the COH protocol. However, at the time of retrieval, we observed a trend toward increasing number of degenerated oocytes aspirated from small follicles after COH with antagonists. From large follicles, besides the trend to acquire a lower number of PB oocytes after antagonists treatment, aspirated follicles presented a significantly higher proportion of GV oocytes, and significantly lower proportion of GVBD compared to agonists groups. The capacity to resume meiosis is sequentially acquired in relation to follicular growth (16). Follicles recruited by both protocols vary in many aspects. In agonists desensitization cycles (long protocols), small antral follicles are recruited by the exogenous gonadotrophins after a variable period of endogenous gonadotrophin depletion. This population of follicles differs from the one recruited in antagonists cycles, which have been exposed for a few days to the endogenous inter-cycle FSH rise (1 3). The microenvironment of the oocyte might, therefore, be different in many aspects, and this hypothetically could explain the observed differences in nuclear maturation stages of oocytes. Whether antagonists treatment matures follicles to a less developed stage needs to be investigated. Research on the content and ratio of various proteins present in follicular fluid at retrieval after various COH protocols should prove helpful. Overall, the results of this study indicate the greater heterogeneity in follicle and/or oocyte development in patients receiving antagonists protocols. When we analyzed oocyte quality among the different follicle diameters of the same patient, we found that PB oocytes originating from small follicles had similar fertilization and developmental potential rates compared with PB originating from large follicles. Still, on day 3 after ICSI a statistically significant proportion of embryos derived from small follicles were retarded in their development (containing not more than four cells) compared with embryos derived from large follicles. Moreover, the rate of embryos presenting a higher number of cells, reaching the eight-cell stage, was less in small follicles group. Several studies indicate that a correlation exists between oocyte developmental competence and follicular size (16 18). The present findings indicate that there is a propensity for a lower developmental capacity when embryos are generated from in vivo matured oocytes of small antral follicles. Therefore, when aspirating these oocytes, one must take into account the differences in development when compared with oocytes from larger follicles. Although PB oocytes of small follicles can eventually be selected for transfer and/or freezing, more studies are needed to know to what extent they 582 Nogueira et al. Oocyte development and follicle size Vol. 85, No. 3, March 2006
6 form viable pregnancies, as their developmental rate is reduced on day 3 after ICSI. The pregnancy rate was not analyzed in our study because we could not relate the embryos that implanted to the follicle sizes. The collection of oocytes from small follicles could offer an extra source of matured oocytes for research. In conclusion, this study demonstrated the greater heterogeneity in the population of oocyte stages that are present in cycles using an antagonist protocol. Although the profile of nuclear maturation in oocytes retrieved after use of antagonist or agonist protocols differs, no statistically significant differences were found in the outcome of ICSI. These results suggest that in vivo matured oocytes derived from 12 mm follicles differ qualitatively from their counterparts derived from larger follicles. When oocytes from smaller follicles are used clinically, it must be taken into account that the resulting embryos will tend to have lower rates of embryonic development. Acknowledgments: The authors thank the embryologists Dr. D. Strassburger, Dr. O. Bern, M.Sc., E. Kasterstein, B.Sc., D. Komarovsky, and the medical staff at the Infertility Unit, Assaf Harofeh Medical Center-Tel Aviv University for their kind collaboration to this project. We also thank Dr. David Keefe for kindly reviewing the manuscript. REFERENCES 1. Elter K, Nelson LR. Use of third generation gonadotrophinfreleasing hormone antagonists in in vitro fertilization embryo transfer: a review. Obstet Gynecol Surv 2001;56: Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2001;(4): CD Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 2002;8: Hernandez ER. Embryo implantation and GnRH antagonists. Embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod 2000; 15: Wittmaack FM, Tureck RW, Kreger DO, Mastroianni L Jr, Blasco L, Lessey BA. Effect of follicular size on oocyte retrieval, fertilization, cleavage and embryo quality in in vitro fertilization cycles: a 6-years data collection. Fertil Steril 1994;62: Dubey AK, Wang HA, Duffy P, Penzias AS. The correlation between follicular measurements, oocyte morphology and fertilization rates in an in vitro fertilization program. Fertil Steril 1995;64: Miller KF, Goldberg JM, Falcone T. Follicle size and implantation of embryos from in vitro fertilization. Obstet Gynecol 1996;88: Ectors FJ, Vanderzwalmen P, Hoeck JV, Nijs M, Verhaegen G, Delvigne A, Schoysman R, Leroy F. Relationship of human follicular diameter with oocyte fertilization and development after in-vitro fertilization or intracytoplasmic sperm injection. Hum Reprod 1997;12: Bergh C, Broden H, Lundin K, Hamberger L. Comparison of fertilization, cleavage and pregnancy rates of oocytes from large and small follicles. Hum Reprod 1998;13: Sereepapong W, Ahnonkitpanit V, Chompurat D, Pansatha J, Suwajanakorn S, Pruksananonda K, et al. Correlation between human follicular diameter and oocyte recovery, metaphase II oocytes and fertilization rate in intracytoplasmic sperm injection programs. J Med Assoc Thai 2001;84(Suppl 1): Triwitayakorn A, Suwajanakorn S, Pruksananonda K, Sereepapong W, Ahnonkitpanit V. Correlation between human follicular diameter and oocyte outcomes in an ICSI program. J Assist Reprod Genet 2003;20: Scott RT, Hofmann GE, Muasher SJ, Acosta AA, Kreiner DK, Rosenwaks Z. Correlation of follicular diameter with oocyte recovery and maturity at the time of transvaginal follicular aspiration. J In Vitro Fert Embryo Transf 1989;6: Smitz J, Janssenswillen C, Liu J, et al. Retrospective analysis of superovulated cycles for ICSI yielding an increased number of immature oocytes. In: Proceedings of the 26th annual conference of the Australian Society for Reproductive Biology. Brisbane, Australia: Australian Society for Reproductive Biology, 1994: abstract Oktay K, Briggs D, Gosden RG. Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab 1997;82: Kol S, Lightman A, Hillensjo T, Devroey P, Fauser B, Tarlatzis B, et al. High doses of gonadotrophin-releasing hormone antagonist in invitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Hum Reprod 1999;14: Mermillod P, Oussaid B, Cognie Y. Aspects of follicular and oocyte maturation that affect the developmental potential of embryos. J Reprod Fertil Suppl 1999;54: Crozet N, Ahmed-Ali M, Dubos MP. Developmental competence of goat oocytes from follicles of different size categories following maturation, fertilization and culture in vitro. J Reprod Fertil 1995;103: Marchal R, Vigneron C, Perreau C, Bali-Papp A, Mermillod P. Effect of follicular size on meiotic and developmental competence of porcine oocytes. Theriogenology 2002;57: Fertility and Sterility 583
Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.
UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,
More informationComparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization
Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization Peter Kovacs, M.D., a Timea Kovats, M.D., a Artur Bernard,
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationA Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist
1 *, ** * * * ** A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist Yoon Sung Nam, Nam Keun Kim*, Eun Kyung Kim**, Hyung Min Chung** and Kwang
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationArticle Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment
RBMOnline - Vol 7. No 2. 185 189 Reproductive BioMedicine Online; www.rbmonline.com/article/900 on web 18 June 2003 Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix,
More informationPremature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles
Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra
More informationVanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol
More informationThe serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
Original Article Obstet Gynecol Sci 2018;61(2):242-246 https://doi.org/10.5468/ogs.2018.61.2.242 pissn 2287-8572 eissn 2287-8580 The serum estradiol/oocyte ratio in patients with breast cancer undergoing
More informationIVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman
IVM in PCOS patients Michael Grynberg René Frydman Department of Obstetrics and Gynecology A. Beclere Hospital, Clamart, France Maribor, Slovenia, 27-28 February 2009 Introduction (1) IVM could be a major
More informationMenstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
Human Reproduction Vol.21, No.4 pp. 1012 1017, 2006 Advance Access publication December 8, 2005. doi:10.1093/humrep/dei415 Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Kasum M., Kurdija K., Orešković S., Čehić E., Pavičić-Baldani D., Škrgatić L. (2016) Combined ovulation triggering with GnRH agonist and hcg in IVF patients. Gynecological
More informationStudy on Several Factors Involved in IVF-ET of Human Beings
Study on Several Factors Involved in IVF-ET of Human Beings Lei X 1, Zhuoran W 1, Bin L 1, Huiming L 1, Hongxiu Z 1, Yajuan Z 1, Yingbo Q 1, Guixue Z 2 1 The First Clinical College of Harbin Medical University,
More informationOocyte maturation. A.Trounson 1 ' 3, C.Anderiesz 1, G.MJones 1, A.Kausche 1, N.Lolatgis 2 and C.Wood 2
A.Trounson 1 ' 3, C.Anderiesz 1, G.MJones 1, A.Kausche 1, N.Lolatgis 2 and C.Wood 2 Centre for Early Human Development, Institute of Reproduction and Development, Monash University, Monash Medical Centre,
More informationORIGINAL ARTICLE. Introduction. Hyo Young Park 1, Min Young Lee 2, Hyo Young Jeong 2, Yong Sook Rho 2, Sang Jin Song 1, Bum-Chae Choi 2
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):62-66 Efficacy of corifollitropin alfa followed by recombinant follicle-stimulating hormone in a gonadotropinreleasing hormone
More informationOriginal Article Effects of a low hcg dose of 2000 IU on clinical outcomes of high-responder women undergoing IVF/ICSI
Int J Clin Exp Med 2016;9(7):14677-14683 www.ijcem.com /ISSN:1940-5901/IJCEM0026636 Original Article Effects of a low hcg dose of 2000 IU on clinical outcomes of high-responder women undergoing IVF/ICSI
More informationFollicular fluid steroid hormone levels are associated with fertilization outcome after intracytoplasmic sperm injection
Follicular fluid steroid hormone levels are associated with fertilization outcome after intracytoplasmic sperm injection Julie D. Lamb, M.D., a A. Musa Zamah, M.D., Ph.D., a Shehua Shen, M.D., a Charles
More informationOvarian response in three consecutive in vitro fertilization cycles
FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Ovarian response in
More informationPossible factors affecting the development of oocytes in in-vitro maturation
Human Reproduction Vol. 15, (Suppl. 5) pp. 11-17, 2000 Possible factors affecting the development of oocytes in in-vitro maturation Anne Lis Mikkelsen 1 ' 2, Steven Smith 1 and Svend Lindenberg 1 ^he Fertility
More informationInfertility treatment
In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation
More informationRelevance of LH activity supplementation
Relevance of LH activity supplementation in ovulation induction Franco Lisi Servizio di Fisiopatologia della Riproduzione Clinica Villa Europa Roma, Italia Comprehension of the role of LH in follicular
More informationInfertility Clinical Guideline
Infertility Clinical Guideline Ovarian Stimulation Guideline Purpose: To provide sufficient background regarding various ovarian stimulation protocols for In Vitro Fertilization cycles. Goal: To assist
More informationA comparative study between agonist and antagonist protocol for ovarian stimulation in art cycles at a rural set up in South Gujarat
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Nadkarni PK et al. Int J Reprod Contracept Obstet Gynecol. 2015 Jun;4(3):617-621 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationThe Comparison of Clinical Outcomes between GnRH Agonist Long Protocol and GnRH Antagonist Short Protocol in Oocyte Donation Cycles
: 30 1 2003 Kor J Fertil Steril, Vol 30, No 1, 2003, 3 The Comparison of Clinical Outcomes between GnRH Agonist Long Protocol and GnRH Antagonist Short Protocol in Oocyte Donation Cycles Jeong Ho Rhee,
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationAlternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment
Human Reproduction Vol., No.11 pp. 319 3197, 5 Advance Access publication July 1, 5. doi:.93/humrep/dei Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to
More informationShould we advise patients undergoing IVF to start a cycle leading to a day 3 or a day 5 transfer?
Human Reproduction Vol.19, No.11 pp. 2550 2554, 2004 Advance Access publication August 6, 2004 doi:10.1093/humrep/deh447 Should we advise patients undergoing IVF to start a cycle leading to a day 3 or
More informationArticle Effect of gonadotrophin priming on in-vitro maturation of oocytes collected from women at risk of OHSS
RBMOnline - Vol 13. No 3. 2006 340 348 Reproductive BioMedicine Online; www.rbmonline.com/article/2328 on web 12 June 2006 Article Effect of gonadotrophin priming on in-vitro maturation of oocytes collected
More informationInternational Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, ISSN
http://www.ijwhr.net Open Access doi 10.15296/ijwhr.2018.31 Original Article International Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, 187 191 ISSN 2330-4456 Comparison
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationH.Van de Velde 1, Z.P.Nagy, H.Joris, A.De Vos and A.C.Van Steirteghem
Human Reproduction vol.12 no.10 pp.2246 2250, 1997 Effects of different hyaluronidase concentrations and mechanical procedures for cumulus cell removal on the outcome of intracytoplasmic sperm injection
More informationTimur Giirgan, M.D.* Bulent Urman, M.D. Hakan Yarali, M.D. Hakan E. Duran, M.D.
FERTILITY AND STEFULI~ Vol. 68, No. 3, September 1997 Copyright 1997 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Published by Elsevier Science Inc. Follicle-stimulating
More informationDoes previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationRafael A. Cabrera, M.D., Laurel Stadtmauer, M.D., Ph.D., Jacob F. Mayer, Ph.D., William E. Gibbons, M.D., and Sergio Oehninger, M.D., Ph.D.
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant
More informationA prospective randomized study comparing aspiration only with aspiration and flushing for transvaginal ultrasound-directed oocyte recovery
FERTILITY AND STERILITY Vol. 58, No.2, August 1992 Copyright e 1992 The American Fertility Society Printed on acid-free paper in U.S.A. A prospective randomized study comparing aspiration only with aspiration
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationTreatment of Poor Responders
Treatment of Poor Responders Pathophysiology of Poor Responders Deficiency in systemic IGF 1 levels (Bahceci, 2007) Lower intra ovarian T levels Reduced FSH receptor expression (Cai, 2007) Bahceci, 2007,
More information2015 Mar.; 26(1):
Journal of Reproduction & Contraception doi: 10.7669/j.issn.1001-7844.2015.01.0022 2015 Mar.; 26(1):22-30 E-mail: randc_journal@163.com Clinical outcomes of using three gonadatropins and medroxyprogestrone
More informationOVULATION INDUCTION. Ori Nevo, M.D., a Talia Eldar-Geva, M.D., Ph.D., b Shahar Kol, M.D., a and Joseph Itskovitz-Eldor, M.D., D.Sc.
FERTILITY AND STERILITY VOL. 79, NO. 5, MAY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. OVULATION INDUCTION Lower levels
More informationProgesterone and clinical outcomes
Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and
More informationReproductive BioMedicine Online (2010) 20, 634 638 www.sciencedirect.com www.rbmonline.com ARTICLE In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing
More information2013 Sep.; 24(3):
Journal of Reproduction & Contraception doi: 10.7669/j.issn.1001-7844.2013.03.0151 2013 Sep.; 24(3):151-158 E-mail: randc_journal@163.com Reducing the Trigger Dose of Human Chorionic Gonadotrophin Does
More informationAsimina Tavaniotou 1, Carola Albano 1, Johan Smitz 1 and Paul Devroey 1,2
Human Reproduction Vol.16, No.4 pp. 663 667, 2001 Comparison of LH concentrations in the early and midluteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist
More informationHerjan Coelingh Bennink, M.D.:j: Andre Van Steirteghem, M.D., Ph.D.* Paul Devroey, M.D., Ph.D.*
J FERTILITY AND STERILITY@ Copyright 't; 1996 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing
More informationPredictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older
Reprod Med Biol (2009) 8:145 149 DOI 10.1007/s12522-009-0023-z ORIGINAL ARTICLE Predictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older Akihisa
More informationA prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF
FVV IN OBGYN, 2012, 4 (2): 82-87 Original paper A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF S. GORDTS,
More informationMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
More informationINDICATIONS OF IVF/ICSI
PROCESS OF IVF/ICSI INDICATIONS OF IVF/ICSI IVF is most clearly indicated when infertility results from one or more causes having no other effective treatment; Tubal disease. In women with blocked fallopian
More informationArticle Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles
RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist
More informationFactors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):67-71 Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles Ju Hee Park
More informationI. ART PROCEDURES. A. In Vitro Fertilization (IVF)
DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationAbstract. Introduction. RBMOnline - Vol 7. No Reproductive BioMedicine Online; on web 16 July 2003
RBMOnline - Vol 7. No 3. 301 308 Reproductive BioMedicine Online; www.rbmonline.com/article/903 on web 16 July 2003 Article Comparable effectiveness using flexible singledose GnRH antagonist (cetrorelix)
More informationIs it the seed or the soil? Arthur Leader, MD, FRCSC
The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events
More informationArticle Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study
RBMOnline - Vol 13. No 2. 2006 166-172 Reproductive BioMedicine Online; www.rbmonline.com/article/2261 on web 19 May 2006 Article Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study
More informationMaria A. Manzanares, M.D., Jose Lui Gomez-Palomares, M.D., Elisabetta Ricciarelli, M.D., and Eleuterio R. Hernandez, M.D., Ph.D.
Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol
More informationLiyan Duan 1, Shihua Bao 1, Kunming Li 1, Xiaoming Teng 1, Ling Hong 1 and Xiaoyu Zhao 2. Abstract. Introduction
doi:10.1111/jog.13305 J. Obstet. Gynaecol. Res. Vol. 43, No. 6: 1037 1042, June 2017 Comparing the long-acting and short-acting forms of gonadotropin-releasing hormone agonists in the long protocol of
More informationUse of in vitro maturation for fertility preservation
Use of in vitro maturation for fertility preservation G. Arroyo Servei de Medicina de la Reproducció Departament d Obstetrícia, Ginecologia i Reproducció INSTITUT UNIVERSITARI DEXEUS MEDICAL STRATEGY TO
More informationEHY Ng, WSB Yeung, PC Ho. Introduction
Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: prospective randomised double-blind study EHY Ng, WSB Yeung, PC Ho
More informationDay 4 embryo selection is equal to Day 5 using a new embryo scoring system validated in single embryo transfers
Human Reproduction Vol.23, No.7 pp. 1505 1510, 2008 Advance Access publication on February 21, 2008 doi:10.1093/humrep/dem419 Day 4 embryo selection is equal to Day 5 using a new embryo scoring system
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationIVF treatment should not be postponed for patients with high basal FSH concentrations
Reproductive BioMedicine Online (2010) 21, 631 635 www.sciencedirect.com www.rbmonline.com SHORT COMMUNICATION IVF treatment should not be postponed for patients with high basal FSH concentrations Ettie
More informationPituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.
UvA-DARE (Digital Academic Repository) Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. Link to publication Citation for published version (APA): Mochtar, M. H.
More informationICSI Cycle with a Sperm from TESE versus From Ejaculate in Oligospermic Men
ICSI Cycle with a Sperm from TESE versus From Ejaculate in Oligospermic Men Hassan S.O. Abduljabbar Ohoud Al-Shamrani Osama Bajouh King Abdulaziz University, P.O.Box 8215 Jeddah 21452, Kingdom of Saudi
More informationDoes triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
More informationOriginal Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and embryo transfer
Int J Clin Exp Med 2015;8(7):11327-11331 www.ijcem.com /ISSN:1940-5901/IJCEM0008838 Original Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and
More informationENDOCRINE CHARACTERISTICS OF ART CYCLES
ENDOCRINE CHARACTERISTICS OF ART CYCLES DOÇ. DR. SEBİHA ÖZDEMİR ÖZKAN KOCAELI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, IVF UNIT 30.04.2014, ANTALYA INTRODUCTION The endocrine
More informationInfluence of GnRH antagonist in reproductive women on in vitro fertilization and embryo transfer in fresh cycles
BIOMEDICAL REPORTS 10: 113-118, 2019 Influence of GnRH antagonist in reproductive women on in vitro fertilization and embryo transfer in fresh cycles YANG XU 1,2, YU SONG ZHANG 3, DONG YI ZHU 2,3, XIANG
More informationOptimal ICSI timing after the first polar body extrusion in in vitro matured human oocytes
Human Reproduction Vol.22, No.7 pp. 1991 1995, 2007 Advance Access publication on May 18, 2007 doi:10.1093/humrep/dem124 Optimal ICSI timing after the first polar body extrusion in in vitro matured human
More information- Meta. : (rfsh); (ufsh); (IVF); : R711.6 : A : X(2015) : hmg( FSH LH) [ufsh, (ufsh-p) (ufsh-hp)] (rfsh) [1] 80, rfsh, 90, :
35 2 Vol.35 No.2 2015 2 Feb. 2015 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2015.02.0099 E-mail: randc_journal@163.com (FSH) - Meta FSH ( 400010) : (IVF) (ICSI) (rfsh) (ufsh) (COS) : PubMed
More informationDipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare
Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare Carlo Alviggi The rational of Follicular synchronization
More informationAssisted reproductive technology
Assisted reproductive technology FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Vol. 62, No.4, October 1994 Printed on acid-free paper in U. S. A. Cryopreservation of supernumerary
More informationPredictive value of embryo grading for embryos with known outcomes
Predictive value of embryo grading for embryos with known outcomes Vanessa N. Weitzman, M.D., Jennifer Schnee-Riesz, M.D., Claudio Benadiva, M.D., John Nulsen, M.D., Linda Siano, M.S., and Donald Maier,
More informationOvarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase
Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase Michael von Wolff, M.D., a Christian J. Thaler, M.D., b Torsten Frambach, M.D., c Cosima Zeeb,
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (4), Page
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (4), Page 858-866 Comparative study between fixed and flexible GnRH antagonist protocol versus GnRH agonist long protocol in polycystic
More informationClinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin
More informationAssisted Reproduction. By Dr. Afraa Mahjoob Al-Naddawi
Assisted Reproduction By Dr. Afraa Mahjoob Al-Naddawi Learning Objectives: By the end of this lecture, you will be able to: 1) Define assisted reproductive techniques (ART). 2) List indications for various
More informationREstradiol and Antagonist Pretreatment Prior to Microdose Leuprolide in in Vitro Fertilization
REstradiol and Antagonist Pretreatment Prior to Microdose Leuprolide in in Vitro Fertilization Does It Improve IVF Outcomes in Poor Responders as Compared to Oral Contraceptive Pill? FTThe Journal of Reproductive
More informationOVULATION INDUCTION. Hsiang, Kaohsiung, Taiwan (FAX: ; adm.cgmh.org.tw).
OVULATION INDUCTION Significantly superior response in the right ovary compared with the left ovary after stimulation with follicle-stimulating hormone in a pituitary down-regulation regimen Kuo-Chung
More informationLan Wang, Yiqing Zhao, Xiyuan Dong, Kai Huang, Rui Wang, Licheng Ji, Ya Wang, Hanwang Zhang
Int J Clin Exp Med 2015;8(2):2711-2718 www.ijcem.com /ISSN:1940-5901/IJCEM0003568 Original Article Could pretreatment with oral contraceptives before pituitary down regulation reduce the incidence of ovarian
More informationIn Vitro Oocyte Maturation: Current Status
199 In Vitro Oocyte Maturation: Current Status Daniela Nogueira, Ph.D. 1 Jean Cl Sadeu, M.D., Ph.D. 2 Jacques Montagut, M.D. 1 1 LaboratoiredeBiologiedelaReproduction IFREARES, Clinique Saint Jean Languedoc,
More informationIn vitro maturation of human oocytes for assisted reproduction
MODERN TRENDS Edward E. Wallach, M.D. Associate Editor In vitro maturation of human oocytes for assisted reproduction Marcus W. Jurema, M.D., and Daniela Nogueira, Ph.D. Department of Obstetrics and Gynecology,
More informationThe effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study
Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi
More information(1.,, ) (2.,,, )
33 11 Vol.33 No.11 2013 11 Nov. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.11.0749 E-mail: randc_journal@163.com IVF-ET 1 2 1 1 1 1 1 (1. 510150) (2. 510150) : (COH) (premature
More informationIN VITRO MATURATION OF HUMAN OOCYTES
REVIEW ARTICLE IN VITRO MATURATION OF HUMAN OOCYTES Yu-Hung Lin 1,2, Jiann-Loung Hwang 1,3 * 1 Department of Obstetrics and Gynecology, Shin Kong Wu Ho-Su Memorial Hospital, 2 School of Medicine, Fu Jen
More informationEvaluation of ovarian response prediction according to age and serum AMH levels in IVF cycles: a retrospective analysis
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Pillai SM et al. Int J Reprod Contracept Obstet Gynecol. 2017 Aug;6(8):3306-3310 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20173190
More informationUse of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF?
Human Reproduction Vol.17, No.8 pp. 2022 2026, 2002 Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF? J.B.Engel, M.Ludwig 1, R.Felberbaum,
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationComparison of GnRH agonist with low-dose urinary hcg for induction of final oocyte maturation
Basrah Journal Of Surgery COMPARISON OF GNRH AGONIST WITH LOW-DOSE URINARY HCG FOR THE INDUCTION OF FINAL OOCYTE MATURATION IN HIGH-RISK PATIENTS UNDERGOING INTRACYTOPLASMIC SPERM INJECTION-EMBRYO TRANSFER
More informationOvarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact
Human Reproduction Page 1 of 5 Hum. Reprod. Advance Access published October 27, 2005 doi:10.1093/humrep/dei371 Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and
More information2017 United HealthCare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1143-4 Program Prior Authorization/Notification Medication Menopur (menotropins) * P&T Approval Date 8/2014, 5/2015, 5/2016, 5/2017
More informationAre all-freeze cycles & frozen-thawed embryo transfers improving IVF outcomes?
Are all-freeze cycles & frozen-thawed embryo transfers improving IVF outcomes? Andrea Weghofer Foundation for Reproductive Medicine 2017 New York, November 16-19 Conflict of interest No relevant financial
More informationCessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multipledose protocol: A randomized controlled study
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2013;40(2):83-89 Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multipledose protocol: A randomized
More informationA comparison of the effects of estrus cow. nuclear maturation of bovine oocytes
A comparison of the effects of estrus cow serum and fetal calf serum on in vitro nuclear maturation of bovine oocytes J Spiropoulos, SE Long University of Bristol, School of Veterinary Science, Department
More informationClinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.
UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,
More informationSynchronization between embryo development and endometrium is a contributing factor for rescue ICSI outcome
Reproductive BioMedicine Online (2012) 24, 527 531 www.sciencedirect.com www.rbmonline.com ARTICLE Synchronization between embryo development and endometrium is a contributing factor for rescue ICSI outcome
More informationA mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort
Chapter 6 A mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort Heijnen E.M., Eijkemans M.J., De Klerk C., Polinder S., Beckers N.G., Klinkert E.R.,
More information